title: The relation of brain ouabain-like compounds and idiopathic intracranial hypertension.
abstract: OBJECTIVE
  To determine the relationship between levels of ouabain-like compounds (OLC) in the cerebrospinal fluid (CSF) and the occurence of idiopathic intracranial hypertension (IIH).
  
  
  BACKGROUND
  OLC are naturally occurring inhibitors of the sodium-potassium ATPase that are found in the CSF of mammals. Since the production of CSF is dependent upon sodium-potassium ATPase activity, and since there is evidence that the increased intracranial pressure found in the condition of IIH may be the result of increased CSF production, we hypothesized that the level of endogenous OLC would be reduced in the CSF of patients with IIH.
  
  
  METHODS
  CSF samples were obtained from n = 7 patients with IIH and n = 31 patients with neurological disorders other than IIH ("control" patients) who had lumbar puncture as part of their routine evaluation or treatment. The concentration of OLC in the CSF samples was measured using an established ELISA.
  
  
  RESULTS
  Patients with IIH exhibited a concentration of OLC in the CSF of 0.11 +/- 0.03 ng/mL. In comparison, the concentration of OLC in CSF samples from non-IIH control patients was 0.12 +/- 0.01 ng/mL. These values were not statistically different when compared with a t-test (P= 0.31). However, the concentration of OLC did negatively correlate to the opening pressure on lumbar puncture, but only in the IIH group (r=-0.80, P= .03). Furthermore, IIH patients who were newly diagnosed or who were unsuccessfully treated (n = 5 of 7 IIH patients) exhibited OLC concentrations of 0.06 +/- 0.1 ng/mL, which is nearly lower than that of the control group (P= .06).
  
  
  CONCLUSIONS
  The average concentration of OLC in IIH patients (treated and untreated) is unlikely to be distinguishable from that in non-IIH control patients with other neurological conditions. However, the concentration of OLC may be inversely related to the intracranial pressure in patients with IIH, and it may prove to be lower in the subgroup of untreated and unsuccessfully treated IIH patients.
authors.affiliation: Northern Neurosciences, Inc., Dearborn, MI, USA.
authors.forename: Mark
authors.initials: M
authors.lastname: Borsody
authors.forename: Irene
authors.initials: I
authors.lastname: Semenov
authors.forename: Kathleen
authors.initials: K
authors.lastname: Carroll
authors.forename: Amy
authors.initials: A
authors.lastname: Kessler
authors.forename: Jordan
authors.initials: J
authors.lastname: Dubow
authors.forename: Edward
authors.initials: E
authors.lastname: Olson
authors.forename: Jennifer
authors.initials: J
authors.lastname: Stern
authors.forename: Ana
authors.initials: A
authors.lastname: Barion
authors.forename: Chris
authors.initials: C
authors.lastname: Hammond
authors.forename: Gregory
authors.initials: G
authors.lastname: Van Stavern
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Raizer
authors.forename: Rosalyn
authors.initials: R
authors.lastname: White
authors.forename: Frans
authors.initials: F
authors.lastname: Leenen
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D007427:Intracranial Pressure; D008297:Male; D008875:Middle Aged; D010042:Ouabain / Q000134:cerebrospinal fluid*; D011559:Pseudotumor Cerebri / Q000134:cerebrospinal fluid* / Q000503:physiopathology
chemical_list: D010042:Ouabain